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Cost EffECtivEnEss Evaluation of Canagliflozin in ComBination 
With mEtformin in thE trEatmEnt of tyPE 2 DiaBEtEs mEllitus in 
PolanD
Szmurlo D.1, Drzal R.1, Plisko R.1, Schubert A.2, Skrzekowska-Baran I.3
1HTA Consulting, Krakow, Poland, 2Janssen Cilag Poland, Warszawa, Poland, 3Janssen-Cilag 
Polska, Warszawa, Poland
Objectives: To evaluate the cost-effectiveness of canagliflozin, an active inhibi-
tor of sodium glucose co-transporter – 2 (SGLT2) in dual therapy as add-on to 
metformin compared to sitagliptin and glimepiride. Canagliflozin in clinical trial 
results showed effective glucose reduction, along with other benefits in diabetes 
treatment including weight loss and SBP reduction. Cost effectiveness analyses 
were conducted in the Polish setting from a public perspective in accordance with 
guidelines of Polish HTA Agency (PolAHTA). MethOds: The IMS CORE Diabetes 
Model was used to evaluate the cost-effectiveness of canagliflozin versus the 
aforementioned comparators using Polish-specific data, where available. Direct 
costs were reported in Polish zloty and an annual discount rate of 5% and 3.5% 
were applied on costs and effects respectively. Results: In dual therapy as add-on 
to metformin, canagliflozin 100 mg dominates sitagliptin with average cost savings 
of 2 811 zł and an average QALY gain of 0.06, canagliflozin 300 mg is cost effective 
option in comparison to sitagliptin with an incremental cost effectiveness ratio 
(ICER) of 45 008 zł per QALY and QALY gain of 0.09. As add-on to metformin cana-
gliflozin is a cost effectiveness option in comparison with glimepiride with ICER 
of 28 454 zł and 73 102 zł, QALY gain 0,112 QALY and 0,140 QALY for canagliflozin 
100 mg and 300 mg respectively. All results are below defined in Polish reimburse-
ment act cost-effectiveness threshold. cOnclusiOns: These results suggest that 
adding Canagliflozin to metformin versus sitagliptin or glimepiride in patients 
inadequately controlled with metformin would be a more efficient use of health 
care resources in the Polish setting.
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Cost-EffECtivEnEss of intErvEntions aimED at DECrEasing thE 
numBEr of amPutations among PatiEnts With DiaBEtEs mEllitus
Ignatyeva V.1, Avxentyeva M.1, Galstyan G.R.2, Bregovskiy V.3, Udovichenko O.4
1The Russian Presidential Academy of National Economy and Public Administration, Moscow, 
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Objectives: To evaluate the cost-effectiveness of interventions aimed at decreas-
ing the number of amputations among patients with diabetic foot ulcers (DFU) in 
Russia. MethOds: We have modeled the changes in the annual outcomes (minor 
and major amputations) and costs (services provided in outpatient clinics and hos-
pitals, medications, orthopedic shoes and prosthetic devices and services provided 
in case of amputation) from the perspective of public health and social care. Two 
interventions were assessed: preventive services for patients with the very high risk 
of DFU (additional outpatient visits for foot care and orthopedic shoes) and provi-
sion of care for DFU patients at hospital by multidisciplinary foot care team (MDT). 
The current number of amputations and costs among DFU patients in Russia was 
assessed on the basis of published Russian data and experts’ survey. The expected 
effectiveness of interventions was derived from the international publications. Costs 
were estimated on the basis on reimbursement rates in public medical insurance 
and social care. Results: The implementation of hospital care by MDT for cohort 
of 1000 DFU patients at the current rate of hospitalizations will require additional 
annual spending of € 532,520, and the expected annual number of major amputa-
tions will decrease by 41. The ICER for this intervention is € 12,988 per prevented 
amputation, which is almost 2 times higher than the costs associated with major 
amputation at the current moment. For the preventive services, if all patients are 
compliant, additional costs per prevented amputation are slightly lower - € 10,216, 
but also well above the costs of major amputation. cOnclusiOns: Both interven-
tions require considerable additional budget spending. Preventive measures, if all 
the patients follow the recommendations, are more cost effective than introduction 
of hospital MDT.
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Objectives: Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor 
used in treatment of patients with type 2 diabetes mellitus (T2DM). The objective 
is to estimate the cost-effectiveness of canagliflozin (100mg once daily and 300mg 
once daily) compared with liraglutide in combination with metformin and sulfony-
lurea (SU) for the treatment of T2DM inadequately controlled with metformin and 
SU in France. MethOds: The IMS CORE Diabetes Model was used to project clinical 
and economic outcomes for patients with T2DM treated with canagliflozin or lira-
glutide, each in combination with metformin and SU. Since direct trial data were not 
available, the relative treatment effects on HbA1c, SBP and BMI for liraglutide 1.8mg 
in combination with metformin and SU were derived from a network meta-analysis 
(NMA) of treatment effects at 26 weeks. This study is limited by the absence of direct 
or indirect data on the effect of liraglutide 1.2mg in combination with metformin 
and SU, therefore the relative treatment effects on HbA1cand BMI at 26 weeks for 
liraglutide 1.2mg were estimated using the dose-response relationship from a NMA 
based on treatments in combination with metformin only. French market share 
data were used to weight the results of liraglutide 1.8mg and 1.2mg. Results: 
Canagliflozin 100mg showed cost savings when compared to treatment with lira-
glutide (1,388 € ); incremental QALYs were estimated as -0,035. Canagliflozin 300 
mg was dominant, with cost savings of 1,411 € and relatively small incremental 
QALY gain of 0.003. cOnclusiOns: The analyses found that treatment of T2DM 
with canagliflozin 100mg or 300mg instead of liraglutide as add on to metformin 
Markov/Monte Carlo simulation techniques to describe the long-term incidence 
and progression of diabetes-related complications. It was used to simulate disease 
progression in a cohort of patients with baseline characteristics (mean age 18.6 
years, duration of diabetes 12 years, mean HbA1c 7.5%) and clinical outcomes 
(severe hypoglycaemic event rates; Quality of Life; HbA1c) taken from a recent 
randomised controlled trial (Ly et al, 2013). Local treatment and complication cost 
data was used. The main scenario considered in this cost-effectiveness analysis 
was the comparison of sensor-augmented insulin pump (SAP) with low glucose 
suspend (LGS) versus insulin pump alone (CSII). The target population was type I 
hypo-prone diabetes patients with the analysis based on a deterministic micro-
simulation of 1,000 patients, using a 5 year time horizon. Direct costs were calcu-
lated from a third-party payer perspective. Discount rates of 3% per annum were 
applied to both costs and clinical outcomes. Results: The Incremental-Cost-
Effectiveness-Ratio (ICER) for SAP+LGS (vs CSII) was € 17,893 per Quality-Adjusted-
Life-Year gained over a 5 year time horizon. Results were similar across a 1 to 10 
year time horizon. Other extensive sensitivity analyses showed the robustness 
of the results. cOnclusiOns: Using a payer’s perspective, our analysis showed 
that SAP (w LGS) is cost-effective over a short term (5 year) time horizon in hypo-
prone Type 1 Diabetes patients in Slovakia (using a WTP threshold of 1x [€ 18,000] 
or 3x [€ 54,000] Slovakia GDP).
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is a homE BasED viDEo tElEConCultation sEtuP Cost EffECtivE for 
loWEring hBa1C for PatiEnts With tyPE-2 DiaBEtEs ovEr a six-month 
PErioD?
Jensen M.S.1, Rasmussen O.W.2
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Objectives: A RCT assessed the effectiveness and costs of a home based video 
teleconsultation (HVT) setup to lower HbA1c in patients with type-2 diabetes 
against usual out-patient treatment on the hospital. The HVT equipment was 
delivered to the patients by the hospital. This analysis shows the potential incre-
mental cost-effectiveness ratio (ICER) of using a HVT setup on six-months health 
care effects and costs. MethOds: The study effectiveness outcome was HbA1c 
level in %. The economic analysis was performed with a spreadsheet decision 
tree model with a Danish hospital payer’s direct cost perspective. Cost data were 
based on study measured time consumption pr. HVT, consultations at out-patient 
clinic, HVT-equipment, -subscription, -support costs, and hospital operating cost. 
Medicine costs weren’t included in the model. Model output included the cost 
of a 1 % point reduction of HbA1c, ICER, with a probabilistic sensitivity analysis 
(PSA). Two scenario analyses (SA) were made to capture costs of patient transport 
to the hospital and a future online platform, were patients can use their own 
computer/tablet to the video teleconsultations. Results: A total of 39 patients 
(mean age 62, HbA1c 8.5%) were randomized to either usual care (UC) or HVT. At 
6 months follow up the HVT group showed greater improvements from baseline 
HbA1c levels (-1.38% vs. -0.92%) and less costly (€ 199.9 vs. € 208.2) against UC. The 
base case ICER showed a potential € –17.58 saving per reduction of 1% HbA1c point. 
A PSA confirmed the ICER trends despite data uncertainties. Both SA showed 
further savings (ICER: € -67.85 and € -69.13). Compliance was 100% for HVT group 
were several planned visits were cancelled in the UC group. cOnclusiOns: The 
present analysis shows the potential benefits of a HVT setup on 6-months health 
care cost and effects against UC. Further savings could include cost associated 
with lost work days.
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Bacon T.1, Willis M.2, Johansen P.2, Neslusan C.3, Nuhoho S.4, Worbes-Cerezo M.5
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Objectives: Sulphonylureas (SU) and insulin are used routinely in the manage-
ment of T2DM but are associated with weight gain and increased risk of hypogly-
caemia. Canagliflozin is a new insulin-independent oral glucose lowering agent 
with added benefits of weight loss, blood pressure reduction and no increased risk 
of hypoglycaemia. This analysis estimated the cost-effectiveness of canagliflozin 
compared to either SU or insulin in patients failing to achieve glycaemic control 
on metformin monotherapy in Ireland. MethOds: The Economic and Health 
Outcomes Model of T2DM (ECHO-T2DM) was used to simulate the lifetime out-
comes and costs associated with canagliflozin (100mg, titrated to 300mg as needed 
to maintain glycaemic control) versus SU and versus insulin glargine. Patient 
characteristics and treatment effects for the SU comparison were sourced from a 
head-to-head randomized clinical trial vs. glimepiride. Hypoglycaemia rates were 
halved to reflect gliclazide MR (the preferred SU in Ireland). Patient characteristics 
for the insulin glargine comparison were obtained from the pooled canagliflo-
zin add-on to metformin RCTs; treatment effects were sourced from a network 
meta-analysis. Costs were localised and inflated to 2013 euros. Utilities were 
sourced from the literature. Costs and outcomes were discounted at 5% annu-
ally. Results: The incremental costs, QALY gains and ICERs associated with 
canagliflozin were € 2,404, 0.215 QALYs and € 11,191 per QALY gained, respectively, 
versus SU and € 2,352, 0.228 QALYs and € 10,305 per QALY gained, respectively, 
versus insulin glargine. Key drivers were decreased hypoglycaemia and lower 
weight-related disutility versus both comparators, as well as better HbA1c durabil-
ity versus SU. In both cases, using an acceptable Irish willingness-to-pay threshold, 
the probability of being cost-effective was in excess of 97%. Sensitivity analyses 
support the robustness of these results. cOnclusiOns: These simulations sug-
gest that canagliflozin is a cost-effective treatment choice versus both gliclazide 
MR and insulin glargine in patients failing to control glycaemia on metformin 
alone.
 VA L U E  I N  H E A LT H  1 7  ( 2 0 1 4 )  A 3 2 3 – A 6 8 6  A347
quality-adjusted life years (QALYs) were calculated from utility data sourced from 
the published literature. The cost-effectiveness was reported as an incremental 
cost-effectiveness ratio (ICER). To assess uncertainty, univariate deterministic and 
multivariate probabilistic sensitivity analyses (PSA) were performed. Results: 
Compared to the DPP4i class, dapagliflozin was associated with 0.023 incremental 
QALYs (95% CI: -0.058, 0.105), at an additional cost of £253 (95% CI: -£302, £741). This 
resulted in an ICER of £10,995 per QALY gained. The incremental cost associated with 
dapagliflozin was primarily due to the additional drug acquisition cost, whereas the 
QALY gain estimated was associated with superior weight reduction and its impact 
on health-related quality of life for dapagliflozin relative to the DPP4i’s. Univariate 
analyses demonstrated that the ICER was most sensitive to varying the weight 
change parameter for the comparator DPP4i’s according to the 95% credible intervals 
in the NMA, giving ICER estimates ranging from £3,937 to £16,727. Dapagliflozin 
had a 59% probability of being cost-effective versus DPP4i’s at a willingness-to-
pay threshold of £20,000 per QALY gained. cOnclusiOns: Dapagliflozin as triple 
therapy in combination with met+SU was shown to be a cost-effective treatment 
option from a UK health care perspective for patients with T2DM who are inad-
equately controlled on met+SU.
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Cost-EffECtivEnEss of saxagliPtin ComParED to glP-1 analoguEs as 
an aDD-on to insulin in thE trEatmEnt of tyPE 2 DiaBEtEs mEllitus 
from a uk hEalth CarE PErsPECtivE
Charokopou M.1, Vioix H.2, Verheggen B.1, Eddowes L.A.3, Griffiths M.4, Gabriel Z.2, Tolley K.5, 
Sibartie M.2
1Pharmerit International, Rotterdam, The Netherlands, 2AstraZeneca UK Ltd., Luton, UK, 3Costello 
Medical Consulting Ltd., Cambridge, UK, 4Costello Medical Consulting, Cambridge, UK,  
5Tolley Health Economics Ltd., Buxton, Derbyshire, UK
Objectives: To assess the cost-effectiveness of saxagliptin, a dipeptidyl pepti-
dase-4 inhibitor (DPP4i), compared to the glucagon-like peptide-1 (GLP-1) analogues, 
exenatide twice-daily or lixisenatide, when added to insulin (±metformin) for the 
treatment of patients with type 2 diabetes mellitus (T2DM) who are inadequately 
controlled on insulin. MethOds: The validated CARDIFF diabetes model was used 
to conduct the analyses. Clinical inputs for the model were sourced from a system-
atic review and network meta-analysis (NMA), which found that the treatments 
were similarly effective at lowering HbA1c and that the GLP-1 analogues resulted 
in greater and clinically relevant weight loss. A UK health care perspective was 
used for costs, and quality-adjusted life years (QALYs) were calculated from util-
ity data sourced from the published literature. To assess uncertainty, univariate 
deterministic and multivariate probabilistic sensitivity analyses (PSA) were per-
formed. Results: Saxagliptin was found to dominate lixisenatide in the base case, 
being associated with lower costs (-£472 [95%CI: -1,378, -223]) and slightly more 
QALYs (0.010 [95%CI: -0.040, 0.076]). Saxagliptin was less costly (-£1,402 [95%CI: 
-£1,932, -£1,218]) and slightly less effective (-0.012 QALYs [95%CI: -0.054, 0.035]) than 
exenatide twice-daily. The lower costs associated with saxagliptin were primarily 
due to the lower drug acquisition costs. The estimated QALY differences were small 
and associated with the impact of weight reduction on health-related quality of 
life. Univariate sensitivity analyses demonstrated that the results were most sensi-
tive to varying the HbA1c treatment effect and the effect of saxagliptin on weight 
change. The PSA estimated that saxagliptin had a 70.4% and 34.3% probability of 
being dominant, and a 99.4% and 100% probability of being cost-saving compared to 
lixisenatide and exenatide twice-daily, respectively. cOnclusiOns: Saxagliptin as 
add-on to insulin was shown to be a cost-saving treatment option from a UK health 
care perspective for patients with T2DM who are inadequately controlled on insulin.
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Objectives: To conduct a systematic review of cost-effectiveness, cost-utility and 
cost-benefit studies of new inhibitors of DPP-4 for diabetes treatment versus other 
antidiabetics. MethOds: We searched the CRD York, NICE Health Technology 
Assessment, Tufts CEA Registry, and MEDLINE (PubMed) databases, and grey litera-
ture through 2014 to identify cost-effectiveness, cost-utility and cost-benefit studies 
of new inhibitors of DPP-4 versus other antidiabetics for diabetes treatment. Three 
investigators independently reviewed all potentially relevant titles and abstracts (1st 
screening), and subsequently screened full-text articles (2nd screening), according to 
pre-established inclusion criteria. We restricted our sample to studies with a lifetime 
or near-lifetime horizon, and adopting either a societal or a health care perspective. 
The studies should be available as a full-text publication and published in English, 
French, Spanish, or Portuguese language. A critical appraisal of the methodology and 
reporting was performed using the 35item version of the BMJ checklist. Results: 
A total of 57 studies were identified. From these, 17 studies were accepted after the 
1st screening, of which 11 were accepted after the 2nd screening. All selected studies 
consisted in cost-utility analyses. Most studies were based on a single randomized 
trial per therapy. Saxagliptin was assessed in 6 studies, Sitagliptin in 4, and vilda-
gliptin in 1. Liraglutide was cost-effective versus sitagliptin as second line therapy 
(ranged from 12,164 to 27,289€ /QALY across countries). Saxagliptin (ranged from 
771 to 10,065 € /QALY across countries), Sitagliptin (ranged from 5,949 € /QALY to 
20,350 € /QALY across countries) and vildagliptin (ICER of 9,072 € / QALY in Portugal) 
were cost-effective versus sulfonylureas as second line therapy. cOnclusiOns: 
According to commonly accepted thresholds, there is consistent evidence about the 
cost-effectiveness of DDP-4 inhibitors as second line therapy for diabetes type 2. 
Though, more evidence (including head-to-head) is necessary to define which DDP-4 
inhibitor is the most cost-effective.
and SU would generate substantial cost savings in France. Canagliflozin 300mg 
showed similar outcomes to liraglutide, suggesting that the treatments are similar 
in effectiveness, and is thus likely to be a highly cost-effective treatment option.
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layEring intErvEntions for tyPE-2 DiaBEtEs PrEvEntion using thE 
sPhr DiaBEtEs moDEl
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Objectives: We have developed a model to evaluate type-2 diabetes prevention 
interventions. The model allows flexible layering of multiple interventions in order to 
determine the optimal combination of strategies for maximal cost-effectiveness. Our 
objective was to demonstrate the utility of the model for analysis of multiple inter-
ventions in different population sub-groups. MethOds: A model of type-2 diabetes 
prevention was developed using a micro-simulation framework. Individual patients 
have simulated trajectories of metabolic factors such as BMI, HbA1c, systolic blood 
pressure and total cholesterol, and can be diagnosed with diabetes, cardiovascular 
disease, cancer, osteoarthritis or microvascular complications of diabetes over the 
course of a lifetime. Interventions targeting metabolic factors influence the likelihood 
of patients developing ill health and dying prematurely. Five interventions were cho-
sen for layering analyses: soft drinks taxation; retail policy; a workplace intervention; 
an educational intervention aimed at deprived individuals; and a diabetes screening 
programme followed by intensive intervention for high risk individuals. Eight dif-
ferent intervention combinations were modelled, using the assumption of either 
additive, synergistic or antagonistic effects in individuals subject to multiple interven-
tions. Results: All interventions generated cost-savings and QALY gains, with the 
screening intervention performing particularly well, followed by the soft drinks tax. 
Combining interventions results in roughly additive effects; this holds whether the 
layering is additive, synergistic or antagonistic due to the relatively low proportions 
of individuals subject to multiple interventions. Certain pairs of interventions were 
found to be almost as cost-effective as combining all five interventions, in particular, 
a soft drinks tax combined with a screening programme is likely to be one of the most 
cost-effective options. cOnclusiOns: The SPHR Diabetes Model is a useful tool for 
analysing the cost-effectiveness of different diabetes prevention interventions, either 
singly or in combination. This will enable development of intervention strategies 
tailored to the needs of the target population.
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Objectives: To explore the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, as monotherapy for the treatment of type 2 
diabetes mellitus (T2DM) that is inadequately controlled by diet and exercise alone 
in patients who are intolerant to metformin. MethOds: The validated CARDIFF 
diabetes model was used. Clinical inputs for the model were sourced from a sys-
tematic review and network meta-analysis (NMA) in monotherapy. A UK health 
care perspective was used for costs, and quality-adjusted life years (QALYs) were 
calculated from utility data in the published literature. A range of assumptions to 
reflect potential clinical practice were utilised. Alterations to the HbA1c switching 
threshold and assumptions on weight extrapolation were considered, in order to 
investigate the impact of different profiles of weight change and longer-term evi-
dence for the maintenance of weight loss. The cost-effectiveness was reported as an 
incremental cost-effectiveness ratio (ICER). Results: When the model assumptions 
were varied around the HbA1c switching threshold and around the profile of main-
tenance of weight loss to better reflect clinical practice, the ICER point estimates 
ranged from £1,847 to £30,795. The lowest ICER point estimate was associated with 
an assumption of maintaining the weight differential that is created at treatment 
initiation, which is generated by the better weight profile of dapagliflozin compared 
to DPP4i, over the whole time horizon. The highest estimate arose when the weight 
differential was maintained for 2 years and there was a higher switching threshold 
for initiating insulin. cOnclusiOns: Dapagliflozin monotherapy has potential as 
a cost-effective treatment option from a UK health care perspective for patients 
with T2DM who are intolerant to metformin and are inadequately controlled by 
diet and exercise alone, based upon a range of explored scenarios. This study also 
demonstrates the value of performing scenario analysis to inform decision-making.
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Objectives: To assess the cost-effectiveness of dapagliflozin, the first-in-class 
sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared to the dipeptidyl 
peptidase-4 inhibitor (DPP4i) class, when used as triple oral therapy in combina-
tion with metformin and a sulphonylurea (met+SU) for the treatment of patients 
with type 2 diabetes mellitus (T2DM) who are inadequately controlled on met+SU 
alone. MethOds: The validated CARDIFF diabetes model was used. Clinical 
inputs for the model were sourced from a systematic review and network meta-
analysis (NMA) in triple therapy that found clinically relevant differences between 
dapagliflozin and DPP4i’s. A UK health care perspective was used for costs, and 
